Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Metrics to compare | QLGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQLGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −3.8x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −1.3x | 2.0x | 2.6x | |
Price / LTM Sales | - | 25.9x | 3.0x | |
Upside (Analyst Target) | - | 199.4% | 48.7% | |
Fair Value Upside | Unlock | −0.6% | 9.2% | Unlock |